Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL

Published:2024-07 Issue:7 Volume:5 Page:100683
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Yagishita Shigehiro,Goto Yasushi,Nishio Makoto,Akamatsu Hiroaki,Hayashi Hidetoshi,Miura Satoru,Tamada Koji,Kagamu Hiroshi,Hamada Akinobu,Ohuchi Mayu,Gemma Akihiko,Yoshino Ichiro,Misumi Toshihiro,Hata Akito,Hara Satoshi,Kijima Takashi,Masaki Fujita,Iwasawa Shunichiro,Nakagawa Shintaro,Tatsuno Masahiro,Mitsudomi Tetsuya

Funder

Chugai Pharmaceuticals Co Ltd

Publisher

Elsevier BV

Reference28 articles.

1. Immune checkpoint inhibitors in advanced non-small cell lung cancer;Assi;Cancer,2018

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

5. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP